Grey Wolf Therapeutics Closes Oversubscribed $49 Million Series B Financing to Advance First-of-its-Kind Neoantigen Creation Approaches

Premier Syndicate of Life Science Industry Investors led by Pfizer Ventures and Earlybird Venture Capital and including Canaan, Andera Partners, Oxford Science Enterprises and British Patient Capital Proceeds to Support Advancement of Lead Candidate, ERAP1 Inhibitor GRWD5769, into the…

Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.